Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

CD34(+) immunoselected cells for poor graft function following allogeneic BMT.

M Mohty¹, C Faucher, C Chabannon

¹Unité de Transplantation er de Thérapie Cellulaire, Département d'Hématologie, Institut Paoli-Calmettes, Marseilles, France.

|June 5, 2002

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tuberculosis after allogeneic hematopoietic stem cell transplantation: a decade nationwide case-control retrospective study in low-incidence country.

Bone marrow transplantation·2026

Same author

The use of MSCs in steroid-refractory acute GvHD in Europe: a survey from the EBMT cellular therapy & immunobiology working party.

Bone marrow transplantation·2025

Same author

Hypoventilation training including maximal end-expiratory breath holding improves the ability to repeat high-intensity efforts in elite judo athletes.

Frontiers in physiology·2024

Same author

Can an online battery match in-person cognitive testing in providing information about age-related cortical morphology?

Brain imaging and behavior·2024

Same author

Current strategies of cell and gene therapy for solid tumors: results of the joint international ESMO and CTIWP-EBMT survey.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Same author

Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP).

Bone marrow transplantation·2023

A boost of CD34(+) cells can improve poor graft function after allogeneic bone marrow transplant (allo-BMT) when patients have full donor chimerism. This approach offers an alternative for patients without graft rejection.

Area of Science:

Hematology
Immunology
Transplantation

Background:

Poor graft function affects approximately 9% of patients undergoing allogeneic bone marrow transplantation (allo-BMT).
This complication can lead to severe, life-threatening issues without evident graft rejection.
Existing treatments like growth factors, transfusions, and donor lymphocyte infusions may not resolve the issue.

Observation:

Three patients with acute leukemia or myelodysplastic syndrome undergoing allo-BMT experienced prolonged cytopenias.
Standard supportive care and donor leukocyte infusions failed to correct the poor graft function.
A CD34(+) cell boost from HLA-identical siblings was administered to these patients.

Findings:

Patients with full donor chimerism at the time of CD34(+) cell infusion showed rapid improvement in peripheral blood counts.

Related Experiment Videos

The patient with mixed chimerism did not exhibit a positive response to the CD34(+) cell boost.

No patients experienced worsening of graft-versus-host disease (GvHD) after the CD34(+) cell infusion.

Implications:

Positively immunoselected allogeneic CD34(+) cells represent a promising therapeutic option for poor graft function post-allo-BMT.
This strategy may be particularly effective in cases without signs of graft rejection.
Further research is warranted to optimize the use of CD34(+) cell boosts in managing allo-BMT complications.